AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38249987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic
Number of subjects: 112
Study 38249987 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment recommended by GOLD 2019 report
Number of subjects: 112
Study 38249988 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring of heart rate, respiratory rate, and temperature on top of standard care.
Number of subjects: 747
Study 38249988 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (control group).
Number of subjects: 747
Study 38250137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 337
Study 38250251 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal gammopathy (MG) in patients with thrombotic microangiopathy (TMA)
Number of subjects: 84
Study 38250251 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement dysregulation screening
Number of subjects: 84
Study 38250251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic microangiopathy (TMA)
Number of subjects: 84
Study 38250270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 84
Study 38250270 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 84
Study 38250270 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 84
Study 38250275 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) and MRI-navigated rTMS therapy
Number of subjects: 64
Study 38250275 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (first-line treatment for PSD)
Number of subjects: 64
Study 38250282 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day training program based on Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 38250282 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38250659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 0
Study 38250659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38250799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 0
Study 38250799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38251497 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching group (adalimumab-afzb and reference adalimumab)
Number of subjects: 445
Study 38251497 — intervention group
Group type: COMPARATOR
Intervention: Non-switching group (reference adalimumab)
Number of subjects: 445
Study 38251498 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 250 mg induction every 4 weeks for 16 weeks, then every 8 weeks from week 16 to week 52
Number of subjects: 1465
Study 38251498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1465
Study 38251498 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1465
Study 38251504 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab plus placebo
Number of subjects: 173
Study 38251504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab plus methotrexate
Number of subjects: 173
Study 38251524 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg biweekly) plus maximum tolerated dose of methotrexate
Number of subjects: 291
Study 38251524 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg biweekly) plus reduced-dose methotrexate
Number of subjects: 291
Study 38251524 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab plus maximum tolerated dose of methotrexate
Number of subjects: 291
Study 38251524 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus reduced-dose methotrexate
Number of subjects: 291
Study 38251533 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg three times daily)
Number of subjects: 87
Study 38251533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to Riociguat)
Number of subjects: 87
Study 38251563 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 34
Study 38251563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 38251564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg weekly subcutaneously for 12 months in combination with 8 weeks of prednisone (initial doses varied from 20 mg to 60 mg).
Number of subjects: 30
Study 38251564 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg weekly subcutaneously for 12 months in combination with 8 weeks of prednisone.
Number of subjects: 30
Study 38251576 — intervention group
Group type: EXPERIMENTAL
Intervention: Obexelimab 5 mg/kg intravenously every 2 weeks for 24 weeks
Number of subjects: 15
Study 38251576 — intervention group
Group type: EXPERIMENTAL
Intervention: Obexelimab treatment
Number of subjects: 15
Study 38251577 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan
Number of subjects: 331
Study 38251577 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 331
Study 38251589 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg taken orally twice a day for 12 weeks
Number of subjects: 100
Study 38251589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38251590 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986142 100 mg
Number of subjects: 248
Study 38251590 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986142 200 mg
Number of subjects: 248
Study 38251590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 38251601 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (300 mg subcutaneously once a week up to week 4 and every 4 weeks thereafter)
Number of subjects: 52
Study 38251601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously)
Number of subjects: 52
Study 38251601 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 52
Study 38251601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 38251740 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care-bundle intervention
Number of subjects: 0
Study 38251740 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine practices)
Number of subjects: 0
Study 38251740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of care-bundle intervention
Number of subjects: 0
Study 38251754 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of macrogol
Number of subjects: 570
Study 38251754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 570
Study 38251791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexuprazan 40 mg once daily for 4-8 weeks
Number of subjects: 332
Study 38251791 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily for 4-8 weeks
Number of subjects: 332
Study 38251791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexuprazan 40 mg
Number of subjects: 332
Study 38251791 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 332
Study 38251861 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment
Number of subjects: 48
Study 38251861 — intervention group
Group type: COMPARATOR
Intervention: Gel (control group)
Number of subjects: 48
Study 38251897 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic deep brain stimulation (DBS)
Number of subjects: 6
Study 38252170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam 500/137 mg loading dose and 1500/410 mg maintenance infusions q6h
Number of subjects: 0
Study 38252170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam-avibactam 500/167 mg loading dose and 1500/500 mg maintenance infusions q6h for CrCL >50 mL/min
Number of subjects: 0
Study 38252170 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h and continuous infusions of aztreonam-avibactam
Number of subjects: 0
Study 38252170 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading doses of aztreonam-avibactam
Number of subjects: 0
Study 38252172 — intervention group
Group type: EXPERIMENTAL
Intervention: STAMP + CBT app
Number of subjects: 15
Study 38252211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 222
Study 38252250 — intervention group
Group type: EXPERIMENTAL
Intervention: My VA Images mobile application
Number of subjects: 31
Study 38252423 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) treatment
Number of subjects: 0
Study 38252439 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 566
Study 38252439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 566
Study 38252439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 38252440 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate infusion (0.125-M l-glutamic acid at 1.65 mL/kg/h for 2 hours, then halved)
Number of subjects: 791
Study 38252440 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 791
Study 38252481 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ)
Number of subjects: 4556
Study 38252481 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC with dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 4556
Study 38252481 — intervention group
Group type: COMPARATOR
Intervention: Standard SMC (SP-AQ) for children younger than 5 years
Number of subjects: 4556
Study 38252515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA)
Number of subjects: 129
Study 38252515 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 129
Study 38252549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Cannabidiol Treatment
Number of subjects: 0
Study 38252547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol in Cannabis Flower
Number of subjects: 0
Study 38252738 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38252805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bienestar/NEEMA Coordinated School Health Program (BN CSHP)
Number of subjects: 28
Study 38252805 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 38252880 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast imaging and genotyping in CNC patients
Number of subjects: 50
Study 38252880 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PRKAR1A pathogenic variant
Number of subjects: 50
Study 38252880 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at breast cancer diagnosis
Number of subjects: 50
Study 38252880 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial CNC and PRKAR1A pathogenic variants
Number of subjects: 50
Study 38252880 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity at the PRKAR1A locus
Number of subjects: 50
Study 38252901 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Letrozole
Number of subjects: 0
Study 38252908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenously once every 3 weeks for up to 2 years
Number of subjects: 12
Study 38252908 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor and corticosteroids (prednisone 40 mg once daily, the day before and on days 1-3 of each cycle, followed by 20 mg once daily on days 4-6, then 10 mg once daily until the day before each subsequent cycle)
Number of subjects: 12
Study 38252908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 12
Study 38252907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 294
Study 38252907 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 294
Study 38252910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) + Tacrolimus (TACRO) + Prednisone (PRED)
Number of subjects: 8
Study 38252910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI) + Nivolumab (NIVO) + Tacrolimus (TACRO) + Prednisone (PRED)
Number of subjects: 8
Study 38252910 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (NIVO)
Number of subjects: 8
Study 38253133 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate use of esTOCma app (iApp)
Number of subjects: 208
Study 38253133 — intervention group
Group type: COMPARATOR
Intervention: Delayed use of esTOCma app (dApp)
Number of subjects: 208
Study 38253245 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment for patients Inside Dosing Table (n=506)
Number of subjects: 787
Study 38253245 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment for patients Outside Dosing Table (n=209)
Number of subjects: 787
Study 38253245 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment for patients Insufficient Data to Recommend a Dose (n=72)
Number of subjects: 787
Study 38253251 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing of Positive Memories Technique (PPMT)
Number of subjects: 70
Study 38253251 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 70
Study 38253253 — intervention group
Group type: EXPERIMENTAL
Intervention: BPCP Mid P method
Number of subjects: 0
Study 38253253 — intervention group
Group type: EXPERIMENTAL
Intervention: Wald approximate CI
Number of subjects: 0
Study 38253253 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Product Confidence Procedure (BPCP), BPCP Mid P, Rothman-Wilson, Thomas-Grunkemeier, Clopper-Pearson, Wilson
Number of subjects: 0
Study 38253252 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive nurse care management with my hypo compass (psychoeducational intervention)
Number of subjects: 0
Study 38253252 — intervention group
Group type: COMPARATOR
Intervention: Proactive nurse care management without my hypo compass
Number of subjects: 0
Study 38253304 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct TAVR implantation
Number of subjects: 228
Study 38253304 — intervention group
Group type: COMPARATOR
Intervention: BAV pre-TAVR implantation
Number of subjects: 228
Study 38253318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided suprazygomatic maxillary nerve block (5 ml of 0.37% ropivacaine)
Number of subjects: 60
Study 38253338 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of RSVPreF3 OA
Number of subjects: 24967
Study 38253338 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of RSVPreF3 OA (first dose followed by revaccination)
Number of subjects: 24967
Study 38253338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24967
Study 38253436 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAVY (high-load, full-range, supervised twice/week)
Number of subjects: 100
Study 38253436 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAVY (high-load)
Number of subjects: 100
Study 38253436 — intervention group
Group type: COMPARATOR
Intervention: LIGHT (low-load, neutral/mid-range, supervised three times in total)
Number of subjects: 100
Study 38253453 — intervention group
Group type: EXPERIMENTAL
Intervention: Development techniques including logistic regression and supervised machine learning methods
Number of subjects: 0
Study 38253453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 0
Study 38253452 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning implementation package
Number of subjects: 33
Study 38253452 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 33
Study 38253469 — intervention group
Group type: EXPERIMENTAL
Intervention: Boot Camp Translation (BCT) intervention for 11-12-year-olds
Number of subjects: 16
Study 38253469 — intervention group
Group type: COMPARATOR
Intervention: Control group for 11-12-year-olds
Number of subjects: 16
Study 38253469 — intervention group
Group type: EXPERIMENTAL
Intervention: Boot Camp Translation (BCT) intervention for 13-17-year-olds
Number of subjects: 16
Study 38253469 — intervention group
Group type: COMPARATOR
Intervention: Control group for 13-17-year-olds
Number of subjects: 16
Study 38253489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ulcer prevention training for relatives of palliative care patients
Number of subjects: 70
Study 38253489 — intervention group
Group type: COMPARATOR
Intervention: Routine ward discharge training for relatives of palliative care patients
Number of subjects: 70
Study 38253701 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors/ARBs
Number of subjects: 2020
Study 38253701 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 2020
Study 38253886 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted calcium hydroxylapatite (CaHA; Radiesse®) administered via cannula-based subcision technique, total of 12 syringes, 1:1 dilution, across three treatment sessions
Number of subjects: 24
Study 38253897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 8
Study 38253897 — intervention group
Group type: COMPARATOR
Intervention: Normal Hearing Control (HCS)
Number of subjects: 8
Study 38253914 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine plus Exclusive Enteral Nutrition (AZA + EEN)
Number of subjects: 84
Study 38253914 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine alone
Number of subjects: 84
Study 38253933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (hypercalcemia and hyperparathyroidism)
Number of subjects: 69
Study 38253933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (hypercalcemia and high BALP levels)
Number of subjects: 69
Study 38253933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (hypophosphatemia and vitamin D deficiency)
Number of subjects: 69
Study 38253933 — intervention group
Group type: EXPERIMENTAL
Intervention: All clusters
Number of subjects: 69
Study 38253933 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Adragão score
Number of subjects: 69
Study 38253979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne distractor (UNI-Smile Distractor, Titamed, Belgium) combined with a LeFort I level osteotomy without pterygomaxillary disjunction
Number of subjects: 4
Study 38254026 — intervention group
Group type: EXPERIMENTAL
Intervention: Egocentric VSN severity
Number of subjects: 36
Study 38254026 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocentric VSN severity
Number of subjects: 36
Study 38254026 — intervention group
Group type: COMPARATOR
Intervention: Postural control measures (COPvel)
Number of subjects: 36
Study 38254026 — intervention group
Group type: COMPARATOR
Intervention: Weight-bearing asymmetry (WBA)
Number of subjects: 36
Study 38254073 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention
Number of subjects: 376
Study 38254073 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 376
Study 38254130 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg
Number of subjects: 114
Study 38254130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 38254137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) at a flow rate of 40L/min, heated to 37℃ with 100% humidity.
Number of subjects: 120
Study 38254137 — intervention group
Group type: COMPARATOR
Intervention: Room air at a flow rate of 2 L/min.
Number of subjects: 120
Study 38254147 — intervention group
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller® device combined with conventional therapy
Number of subjects: 36
Study 38254147 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 36
Study 38254201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-Aminolevulinic acid (5-ALA) concurrent to radiotherapy (RT) with a maximum of eight fractions of radiodynamic therapy (RDT).
Number of subjects: 30
Study 38254201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-Aminolevulinic acid (5-ALA) concurrent to radiotherapy (RT).
Number of subjects: 30
Study 38254201 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA metabolites and radiobiological markers analysis throughout the course of therapy.
Number of subjects: 30
Study 38254211 — intervention group
Group type: EXPERIMENTAL
Intervention: Azvudine 5 mg daily for a maximum of 7 days
Number of subjects: 1096
Study 38254211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (five tablets daily)
Number of subjects: 1096
Study 38254233 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) with 15 ml of 0.5% ropivacaine administered to T4 and T7 thoracic paravertebral spaces before general anaesthesia induction.
Number of subjects: 302
Study 38254233 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA) without TPVB.
Number of subjects: 302
Study 38254233 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB group
Number of subjects: 302
Study 38254233 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 302
Study 38254266 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 0
Study 38254266 — intervention group
Group type: COMPARATOR
Intervention: Inhibitory anti-uPA antibodies
Number of subjects: 0
Study 38254921 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-Ready mini intervention
Number of subjects: 0
Study 38254921 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38257071 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids, dosage and duration not specified
Number of subjects: 0
Study 38257156 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Bolus (SB)
Number of subjects: 72
Study 38257156 — intervention group
Group type: COMPARATOR
Intervention: Normal Bolus (NB)
Number of subjects: 72
Study 38258270 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-TIV
Number of subjects: 279
Study 38258270 — intervention group
Group type: COMPARATOR
Intervention: SD-QIV
Number of subjects: 279
Study 38258274 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9567 2 mg, 10 mg, 20 mg, 40 mg, 80 mg, 100 mg, 125 mg, or 155 mg (single-ascending dose study)
Number of subjects: 149